RIDR-PI-103

Modify Date: 2024-01-15 10:58:05

RIDR-PI-103 structure	Common Name	RIDR-PI-103
	CAS Number	2581114-71-6	Molecular Weight	511.53
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₂₇H₂₅N₇O₄	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of RIDR-PI-103

RIDR-PI-103 is a reactive oxygen species (ROS)-induced drug release prodrug with a self-cyclizing moiety linked to a pan-PI3K inhibitor (PI-103). Doxorubicin and RIDR-PI-103 shows a synergistic effect in MDA-MB-361 and MDA-MB-231 cells to inhibit cancer cell proliferation[1][2].

Name	RIDR-PI-103

Description	RIDR-PI-103 is a reactive oxygen species (ROS)-induced drug release prodrug with a self-cyclizing moiety linked to a pan-PI3K inhibitor (PI-103). Doxorubicin and RIDR-PI-103 shows a synergistic effect in MDA-MB-361 and MDA-MB-231 cells to inhibit cancer cell proliferation[1][2].
Related Catalog	Research Areas >> Cancer
References	[1]. Mishra R, et al. Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth. Int J Mol Sci. 2021;22(4):2088. Published 2021 Feb 19. [2]. Rosalin Mishra, et al. Efficacy of RIDRPI103, a reactive oxygen species (ROS) activated prodrug in treatment of breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-10-04.

Description

Related Catalog

Research Areas >> Cancer

References

[1]. Mishra R, et al. Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth. Int J Mol Sci. 2021;22(4):2088. Published 2021 Feb 19.

[2]. Rosalin Mishra, et al. Efficacy of RIDRPI103, a reactive oxygen species (ROS) activated prodrug in treatment of breast cancer [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P3-10-04.